madman
Super Moderator
* VAPEUR-RCT trial, which compared Rezūm—a minimally invasive steam therapy for benign prostatic hyperplasia (BPH)—against combination medical therapy (alpha blocker plus 5-alpha reductase inhibitor) in patients already on alpha blocker treatment
* Rezūm outperformed combination medical therapy on both symptom control and sexual function preservation, while sparing patients the well-documented adverse events of long-term medication use.
In this video, Jean-Nicolas Cornu, MD, PhD, FEBU, explains the rationale and key findings of the VAPEUR-RCT trial, which compared Rezūm—a minimally invasive steam therapy for benign prostatic hyperplasia (BPH)—against combination medical therapy (alpha blocker plus 5-alpha reductase inhibitor) in patients already on alpha blocker treatment. Cornu presented the data at 41st Annual Congress of the European Association of Urology in London, the United Kingdom.
The trial was designed to fill a critical evidence gap. Although Rezūm had previously been compared to sham surgery and shown to be effective, no head-to-head data existed against standard drug therapy. Cornu explains that Rezūm occupies a middle ground between medications and invasive surgery, and that its most natural clinical competitor is medical management rather than aggressive surgical options, which typically serve a different patient population. Crucially, patient preference data consistently showed that men with BPH prioritize sexual function preservation—particularly ejaculatory function—alongside symptom relief, making that a co-primary end point alongside International Prostate Symptoms Score (IPSS) improvement.
The findings favor Rezūm on both fronts. At 1 year, patients randomized to Rezūm showed a 4.6-point greater improvement on the IPSS symptom score compared with those escalated to combination therapy—a clinically meaningful difference against a drug regimen whose evidence base dates to 2003. Rezūm patients also demonstrated superior outcomes on the MHQ sexual function questionnaire, with better preservation of sexuality and ejaculation. Cornu notes that numerous secondary end points will require further analysis, but the headline message is clear: Rezūm outperformed combination medical therapy on both symptom control and sexual function preservation, while sparing patients the well-documented adverse events of long-term medication use.
* Rezūm outperformed combination medical therapy on both symptom control and sexual function preservation, while sparing patients the well-documented adverse events of long-term medication use.
In this video, Jean-Nicolas Cornu, MD, PhD, FEBU, explains the rationale and key findings of the VAPEUR-RCT trial, which compared Rezūm—a minimally invasive steam therapy for benign prostatic hyperplasia (BPH)—against combination medical therapy (alpha blocker plus 5-alpha reductase inhibitor) in patients already on alpha blocker treatment. Cornu presented the data at 41st Annual Congress of the European Association of Urology in London, the United Kingdom.
The trial was designed to fill a critical evidence gap. Although Rezūm had previously been compared to sham surgery and shown to be effective, no head-to-head data existed against standard drug therapy. Cornu explains that Rezūm occupies a middle ground between medications and invasive surgery, and that its most natural clinical competitor is medical management rather than aggressive surgical options, which typically serve a different patient population. Crucially, patient preference data consistently showed that men with BPH prioritize sexual function preservation—particularly ejaculatory function—alongside symptom relief, making that a co-primary end point alongside International Prostate Symptoms Score (IPSS) improvement.
The findings favor Rezūm on both fronts. At 1 year, patients randomized to Rezūm showed a 4.6-point greater improvement on the IPSS symptom score compared with those escalated to combination therapy—a clinically meaningful difference against a drug regimen whose evidence base dates to 2003. Rezūm patients also demonstrated superior outcomes on the MHQ sexual function questionnaire, with better preservation of sexuality and ejaculation. Cornu notes that numerous secondary end points will require further analysis, but the headline message is clear: Rezūm outperformed combination medical therapy on both symptom control and sexual function preservation, while sparing patients the well-documented adverse events of long-term medication use.
